Search Results - "Gisslinger, Heinz"

Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials by Gisslinger, Heinz

“…Ropeginterferon alfa-2b (RopegIFN) enables effective cytoreduction in polycythemia vera (PV). Recent analyses suggest that long-term RopegIFN therapy fulfills…”
Get full text

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms by Klampfl, Thorsten, Gisslinger, Heinz, Harutyunyan, Ashot S, Nivarthi, Harini, Rumi, Elisa, Milosevic, Jelena D, Them, Nicole C.C, Berg, Tiina, Gisslinger, Bettina, Pietra, Daniela, Chen, Doris, Vladimer, Gregory I, Bagienski, Klaudia, Milanesi, Chiara, Casetti, Ilaria Carola, Sant'Antonio, Emanuela, Ferretti, Virginia, Elena, Chiara, Schischlik, Fiorella, Cleary, Ciara, Six, Melanie, Schalling, Martin, Schönegger, Andreas, Bock, Christoph, Malcovati, Luca, Pascutto, Cristiana, Superti-Furga, Giulio, Cazzola, Mario, Kralovics, Robert

“…The authors identified calreticulin mutations in the majority of patients with essential thrombocythemia and myelofibrosis who did not have JAK2 mutations. The…”
Get full text

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion by Barbui, Tiziano, Thiele, Jürgen, Gisslinger, Heinz, Kvasnicka, Hans Michael, Vannucchi, Alessandro M., Guglielmelli, Paola, Orazi, Attilio, Tefferi, Ayalew

“…The new edition of the 2016 World Health Organization (WHO) classification system for tumors of the hematopoietic and lymphoid tissues was published in…”
Get full text

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis by Harrison, Claire, Kiladjian, Jean-Jacques, Al-Ali, Haifa Kathrin, Gisslinger, Heinz, Waltzman, Roger, Stalbovskaya, Viktoriya, McQuitty, Mari, Hunter, Deborah S, Levy, Richard, Knoops, Laurent, Cervantes, Francisco, Vannucchi, Alessandro M, Barbui, Tiziano, Barosi, Giovanni

“…Patients with myelofibrosis who were treated with ruxolitinib, a JAK1 and JAK2 inhibitor, showed significant responses with respect to spleen size and quality…”
Get full text

Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis) by Barbui, Tiziano, Finazzi, Guido, Carobbio, Alessandra, Thiele, Juergen, Passamonti, Francesco, Rumi, Elisa, Ruggeri, Marco, Rodeghiero, Francesco, Randi, Maria Luigia, Bertozzi, Irene, Gisslinger, Heinz, Buxhofer-Ausch, Veronika, De Stefano, Valerio, Betti, Silvia, Rambaldi, Alessandro, Vannucchi, Alessandro M., Tefferi, Ayalew

“…Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform for prospective studies exploring preventive measures. Current risk…”
Get full text

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b by Kiladjian, Jean-Jacques, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Gisslinger, Heinz

Get full text

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms by Milosevic Feenstra, Jelena D., Nivarthi, Harini, Gisslinger, Heinz, Leroy, Emilie, Rumi, Elisa, Chachoua, Ilyas, Bagienski, Klaudia, Kubesova, Blanka, Pietra, Daniela, Gisslinger, Bettina, Milanesi, Chiara, Jäger, Roland, Chen, Doris, Berg, Tiina, Schalling, Martin, Schuster, Michael, Bock, Christoph, Constantinescu, Stefan N., Cazzola, Mario, Kralovics, Robert

“…Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic diseases characterized by clonal hematopoiesis and hyperproliferation of terminally…”
Get full text

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma by Palumbo, Antonio, Hajek, Roman, Delforge, Michel, Kropff, Martin, Petrucci, Maria Teresa, Catalano, John, Gisslinger, Heinz, Wiktor-Jędrzejczak, Wiesław, Zodelava, Mamia, Weisel, Katja, Cascavilla, Nicola, Iosava, Genadi, Cavo, Michele, Kloczko, Janusz, Bladé, Joan, Beksac, Meral, Spicka, Ivan, Plesner, Torben, Radke, Joergen, Langer, Christian, Yehuda, Dina Ben, Corso, Alessandro, Herbein, Lindsay, Yu, Zhinuan, Mei, Jay, Jacques, Christian, Dimopoulos, Meletios A

“…Patients treated with an induction regimen of melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance therapy had longer progression-free…”
Get full text

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report by Tefferi, Ayalew, Cervantes, Francisco, Mesa, Ruben, Passamonti, Francesco, Verstovsek, Srdan, Vannucchi, Alessandro M., Gotlib, Jason, Dupriez, Brigitte, Pardanani, Animesh, Harrison, Claire, Hoffman, Ronald, Gisslinger, Heinz, Kröger, Nicolaus, Thiele, Juergen, Barbui, Tiziano, Barosi, Giovanni

“…The current document is a revision of the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria for treatment…”
Get full text

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study by Cervantes, Francisco, Ross, David M., Radinoff, Atanas, Palandri, Francesca, Myasnikov, Alexandr, Vannucchi, Alessandro M., Zachee, Pierre, Gisslinger, Heinz, Komatsu, Norio, Foltz, Lynda, Mannelli, Francesco, Passamonti, Francesco, Gilotti, Geralyn, Sadek, Islam, Tiwari, Ranjan, Zor, Evren, Al-Ali, Haifa Kathrin

“…Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients. The REALISE phase 2 study…”
Get full text

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients by Carobbio, Alessandra, Thiele, Juergen, Passamonti, Francesco, Rumi, Elisa, Ruggeri, Marco, Rodeghiero, Francesco, Randi, Maria Luigia, Bertozzi, Irene, Vannucchi, Alessandro M., Antonioli, Elisabetta, Gisslinger, Heinz, Buxhofer-Ausch, Veronika, Finazzi, Guido, Gangat, Naseema, Tefferi, Ayalew, Barbui, Tiziano

“…In an international collaborative study, a central histologic review identified 891 patients with essential thrombocythemia, strictly defined by World Health…”
Get full text

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms by Kralovics, Robert, Olcaydu, Damla, Harutyunyan, Ashot, Jäger, Roland, Berg, Tiina, Gisslinger, Bettina, Pabinger, Ingrid, Gisslinger, Heinz

“…Genome-wide association studies have identified a number of new disease susceptibility loci that represent haplotypes defined by numerous SNPs. SNPs within a…”
Get full text

Current and future treatment options for polycythemia vera by Griesshammer, Martin, Gisslinger, Heinz, Mesa, Ruben

“…Patients with polycythemia vera (PV), a myeloproliferative neoplasm characterized by an elevated red blood cell mass, are at high risk of vascular and…”
Get full text

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study by BARBUI, Tiziano, THIELE, Juergen, MARINO, Filippo, VANNUCCHI, Alessandro M, ANTONIOLI, Elisabetta, CARRAI, Valentina, GISSLINGER, Heinz, BUXHOFER-AUSCH, Veronika, MÜLLAUER, Leonhard, CAROBBIO, Alessandra, GIANATTI, Andrea, GANGAT, Naseema, PASSAMONTI, Francesco, HANSON, Curtis A, TEFFERI, Ayalew, RUMI, Elisa, BOVERI, Emanuela, RUGGERI, Marco, RODEGHIERO, Francesco, D'AMORE, Emanuele S. G, RANDI, Maria Luigia, BERTOZZI, Irene

“…The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary…”
Get full text

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification by Thiele, Jürgen, Kvasnicka, Hans Michael, Müllauer, Leonhard, Buxhofer-Ausch, Veronika, Gisslinger, Bettina, Gisslinger, Heinz

“…Controversy persists regarding the role of histopathology in the distinction between essential thrombocythemia (ET) and early-prefibrotic primary…”
Get full text

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms by Schischlik, Fiorella, Jäger, Roland, Rosebrock, Felix, Hug, Eva, Schuster, Michael, Holly, Raimund, Fuchs, Elisabeth, Milosevic Feenstra, Jelena D., Bogner, Edith, Gisslinger, Bettina, Schalling, Martin, Rumi, Elisa, Pietra, Daniela, Fischer, Gottfried, Faé, Ingrid, Vulliard, Loan, Menche, Jörg, Haferlach, Torsten, Meggendorfer, Manja, Stengel, Anna, Bock, Christoph, Cazzola, Mario, Gisslinger, Heinz, Kralovics, Robert

“…Ph-negative myeloproliferative neoplasms (MPNs) are hematological cancers that can be subdivided into entities with distinct clinical features. Somatic…”
Get full text

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project by Barosi, Giovanni, Mesa, Ruben, Finazzi, Guido, Harrison, Claire, Kiladjian, Jean-Jacques, Lengfelder, Eva, McMullin, Mary F., Passamonti, Francesco, Vannucchi, Alessandro M., Besses, Carlos, Gisslinger, Heinz, Samuelsson, Jan, Verstovsek, Srdan, Hoffman, Ronald, Pardanani, Animesh, Cervantes, Francisco, Tefferi, Ayalew, Barbui, Tiziano

“…Standardized response criteria to interpret and compare clinical trials are needed for approval of new therapeutic agents by regulatory agencies. The European…”
Get full text

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms by Tapper, William, Jones, Amy V., Kralovics, Robert, Harutyunyan, Ashot S., Zoi, Katerina, Leung, William, Godfrey, Anna L., Guglielmelli, Paola, Callaway, Alison, Ward, Daniel, Aranaz, Paula, White, Helen E., Waghorn, Katherine, Lin, Feng, Chase, Andrew, Joanna Baxter, E., Maclean, Cathy, Nangalia, Jyoti, Chen, Edwin, Evans, Paul, Short, Michael, Jack, Andrew, Wallis, Louise, Oscier, David, Duncombe, Andrew S., Schuh, Anna, Mead, Adam J., Griffiths, Michael, Ewing, Joanne, Gale, Rosemary E., Schnittger, Susanne, Haferlach, Torsten, Stegelmann, Frank, Döhner, Konstanze, Grallert, Harald, Strauch, Konstantin, Tanaka, Toshiko, Bandinelli, Stefania, Giannopoulos, Andreas, Pieri, Lisa, Mannarelli, Carmela, Gisslinger, Heinz, Barosi, Giovanni, Cazzola, Mario, Reiter, Andreas, Harrison, Claire, Campbell, Peter, Green, Anthony R., Vannucchi, Alessandro, Cross, Nicholas C.P.

“…Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2 , CALR or MPL , but the contribution of inherited factors is…”
Get full text

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel by Tefferi, Ayalew, Thiele, Juergen, Orazi, Attilio, Kvasnicka, Hans Michael, Barbui, Tiziano, Hanson, Curtis A., Barosi, Giovanni, Verstovsek, Srdan, Birgegard, Gunnar, Mesa, Ruben, Reilly, John T., Gisslinger, Heinz, Vannucchi, Alessandro M., Cervantes, Francisco, Finazzi, Guido, Hoffman, Ronald, Gilliland, D. Gary, Bloomfield, Clara D., Vardiman, James W.

“…The Janus kinase 2 mutation, JAK2617V>F, is myeloid neoplasm-specific; its presence excludes secondary polycythemia, thrombocytosis, or bone marrow fibrosis…”
Get full text

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis by Durrant, Simon T, Nagler, Arnon, Guglielmelli, Paola, Lavie, David, le Coutre, Philipp, Gisslinger, Heinz, Chuah, Charles, Maffioli, Margherita, Bharathy, Savita, Dong, Tuochuan, Wroclawska, Monika, Lopez, Joaquin Martinez

Get full text